By Gilang Cahya 
In a significant stride toward demystifying the alarming surge in early-onset colorectal cancer, an international consortium of scientists spearheaded by the University of California San Diego has pinpointed a probable microbial instigator: colibactin, a potent bacterial toxin. This groundbreaking research, published in the prestigious journal Nature, sheds new light on a complex medical puzzle, suggesting that exposure to this toxin in early childhood may be laying the groundwork for the disease to manifest decades earlier than historically observed.
The study meticulously analyzed 981 colorectal cancer genomes from individuals across 11 nations, encompassing both early- and late-onset cases. The findings revealed a distinct genetic fingerprint left by colibactin on colon cells, a signature that was found to be a striking 3.3 times more prevalent in individuals diagnosed with colorectal cancer before the age of 40 compared to those diagnosed after age 70. This pattern was particularly pronounced in countries experiencing a higher incidence of early-onset colorectal cancer, underscoring a potential global dimension to this emerging health crisis.
"These mutation patterns serve as a historical record etched within the genome, strongly indicating that early-life exposure to colibactin is a principal driver behind the development of early-onset disease," stated Ludmil Alexandrov, the study’s senior author and a distinguished professor at UC San Diego. His expertise spans bioengineering and cellular and molecular medicine, and he is also a key figure at the UC San Diego Moores Cancer Center and Deputy Director of the Sanford Stem Cell Fitness and Space Medicine Center.
While previous research, including earlier work by Alexandrov’s laboratory, had identified colibactin-related mutations in approximately 10% to 15% of all colorectal cancer cases, those studies often focused on late-onset disease or did not differentiate between age groups. This latest investigation marks a pivotal moment by providing the first definitive evidence of a substantial increase in colibactin-related mutations specifically within the early-onset patient cohort.
The Rising Tide of Early-Onset Colorectal Cancer
Colorectal cancer, once predominantly a disease affecting older adults, has witnessed a disturbing escalation in incidence among younger populations. Current trends indicate that the rate of colorectal cancer in individuals under 50 has nearly doubled each decade over the past 20 years. Projections suggest that if these trends persist, colorectal cancer could become the leading cause of cancer-related mortality among young adults by 2030. This escalating crisis has left medical professionals and researchers grappling for answers, as many young patients diagnosed with the disease lack a family history of cancer or exhibit common risk factors such as obesity or hypertension. This has fueled speculation about the role of previously unidentified environmental or microbial exposures, a hypothesis that this new study directly addresses.
"Our initial objective for this project was not exclusively to zero in on early-onset colorectal cancer," explained Marcos Díaz-Gay, a co-first author of the study and a former postdoctoral researcher in Alexandrov’s lab. "We aimed to conduct a global examination of colorectal cancer patterns to understand disparities in incidence rates across different countries. However, as we delved deeper into the data, the frequent appearance of colibactin-related mutations in early-onset cases emerged as one of our most compelling and unexpected findings."
Colibactin’s Early Imprint on DNA
The research indicates that colibactin’s detrimental effects commence early in life. Through sophisticated molecular timing of the identified mutational signatures, the scientists demonstrated that colibactin-associated mutations emerge at the nascent stages of tumor development. This aligns with prior studies that have suggested such mutations can occur within the first decade of life. Furthermore, the study revealed that colibactin-related mutations constitute approximately 15% of what are classified as "APC driver mutations" – critical early genetic alterations that directly fuel cancer progression – in colorectal cancer.
"If an individual acquires one of these crucial driver mutations by the age of 10," Alexandrov elaborated, "they could be decades ahead of the typical timeline for developing colorectal cancer, potentially experiencing it at age 40 rather than the more common age of 60." This suggests a scenario where colibactin-producing bacteria might silently colonize a child’s colon, initiating fundamental molecular changes in their DNA and inadvertently setting the stage for colorectal cancer development long before any overt symptoms manifest. While the study presents robust evidence supporting this hypothesis, Alexandrov emphasized the need for further research to definitively establish causality.
Building on a Foundation of Mutational Signature Research
This pivotal study is part of the larger Cancer Grand Challenges initiative, specifically the Mutographs team, which is funded by Cancer Research UK. It represents the latest advancement in a body of work that Alexandrov, Díaz-Gay, and their colleagues have been diligently pursuing over several years. Their research has centered on deciphering the distinct patterns of DNA mutations caused by various environmental exposures, including ultraviolet radiation and bacterial toxins, as well as lifestyle choices like smoking and alcohol consumption. Each of these factors leaves a unique genetic "fingerprint" or mutational signature within the genome, offering crucial clues to the origins of specific cancers.
Through a sustained collaboration involving UC San Diego, the International Agency for Research on Cancer (France), and the Wellcome Sanger Institute (UK), supported by Cancer Grand Challenges funding, the Mutographs team has successfully elucidated the mutational processes underlying various cancers globally, including esophageal, kidney, and head and neck cancers. The recent findings on colorectal cancer further expand this comprehensive understanding of cancer etiology through the lens of mutational signature analysis. By systematically cataloging these intricate mutational patterns across thousands of cancer genomes, the researchers aim to identify novel causes of cancer that may have previously eluded detection.
"Not every environmental factor or behavioral habit we investigate leaves an indelible mark on our genome," Alexandrov noted. "However, we have found that colibactin is indeed one of those agents that does. In this instance, its genetic imprint appears to be strongly correlated with colorectal cancers occurring in young adults."
Unanswered Questions and Future Directions
The discovery raises a cascade of critical new questions that demand urgent attention. How are children acquiring exposure to colibactin-producing bacteria? What preventive measures can be implemented to mitigate this exposure? Are specific environmental conditions, dietary habits, or lifestyle choices more conducive to colibactin production? And crucially, how can individuals determine if they have already developed these colibactin-induced mutations?
The research team is actively pursuing several hypotheses to address these inquiries. They are undertaking further investigations into the precise correlation between colibactin exposure and the risk of early-onset colorectal cancer. Additionally, they are exploring the potential of probiotics as a safe and effective means of eliminating harmful bacterial strains. A significant area of development includes the creation of early detection tests that analyze stool samples for the presence of colibactin-related mutations, offering a non-invasive approach to screening.
Global Perspectives and the Long Shadow of Early Life
In parallel with their focused investigation into colibactin, the team continues its broader global quest for cancer-linked mutational signatures. Their recent Nature publication also highlighted increased prevalence of certain mutational signatures in colorectal cancers originating from specific countries, including Argentina, Brazil, Colombia, Russia, and Thailand. This observation strongly suggests that local environmental exposures may play a significant role in contributing to cancer risk within these regions.
"It is plausible that different countries harbor distinct, as-yet-unidentified causes of cancer," commented Díaz-Gay, who is now spearheading a new phase of the study at his recently established laboratory at the Spanish National Cancer Research Center (CNIO) in Madrid. "This could pave the way for the development of targeted, region-specific prevention strategies."
Alexandrov articulated a profound implication of this research: that many cancers might originate from environmental or microbial exposures encountered during early life, long before a diagnosis is made. "This fundamentally shifts our perspective on cancer," he stated. "It may not solely be a consequence of events occurring in adulthood. Cancer development could potentially be influenced by occurrences in early life, perhaps even within the first few years of existence. Sustained investment in this type of research is paramount to our global endeavor to prevent and treat cancer effectively before it becomes too late."
The implications of this research extend beyond the immediate concern of colorectal cancer. It suggests a broader paradigm shift in our understanding of cancer etiology, emphasizing the critical role of early life exposures, both environmental and microbial, in shaping long-term health trajectories. As scientists continue to decode the intricate language of our genomes, insights like these offer hope for developing novel preventative strategies and earlier, more effective interventions against a disease that continues to affect millions worldwide. The identification of colibactin as a key player in the rise of early-onset colorectal cancer is not an endpoint, but rather a crucial stepping stone in a much larger, ongoing scientific journey.
